Glaukos Corp (GKOS) Stock
Key stats
- Market cap
- $14.63B
- Price / Earnings ratio
- -82.3x
- EPS (TTM)
- -$2.95
- Volume
- Loading
- 52-week high
- $255.19
- 52-week low
- $87.32
Source: third-party data provider, as of November 13, 2026
Compare with GKOS
Recent news
Glaukos Announces Participation in Upcoming Investor Conferences
Glaukos Announces Participation in Upcoming Investor Conferences
GKOS
Glaukos Sets $1 Billion 2027 Sales Goal: Rapid Earnings Reaction
Glaukos Sets $1 Billion 2027 Sales Goal: Rapid Earnings Reaction
GKOS
Glaukos (GKOS) Q3 Earnings and Revenues Surpass Estimates
Glaukos (GKOS) Q3 Earnings and Revenues Surpass Estimates
GKOS
Compared to Estimates, Glaukos (GKOS) Q3 Earnings: A Look at Key Metrics
Compared to Estimates, Glaukos (GKOS) Q3 Earnings: A Look at Key Metrics
GKOSNews tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 69.63
- MACD 12/26/9
- 18.90
- EMA 9 of MACD
- 15.80
- MACD histogram
- 3.10
- SMA 50
- $181.98
- Price above SMA 50
- EMA 50
- $190.96
- Price above EMA 50
- SMA 200
- $146.02
- Price above SMA 200
- EMA 200
- $150.44
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 10 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
The market is expecting earnings per share of -$0.05 for this quarter. The company has not yet shared when it is announcing earnings.
Source: third-party data provider
Latest news
Glaukos Announces Participation in Upcoming Investor Conferences
Glaukos Announces Participation in Upcoming Investor Conferences
GKOSGlaukos Sets $1 Billion 2027 Sales Goal: Rapid Earnings Reaction
Glaukos Sets $1 Billion 2027 Sales Goal: Rapid Earnings Reaction
GKOSGlaukos (GKOS) Q3 Earnings and Revenues Surpass Estimates
Glaukos (GKOS) Q3 Earnings and Revenues Surpass Estimates
GKOSCompared to Estimates, Glaukos (GKOS) Q3 Earnings: A Look at Key Metrics
Compared to Estimates, Glaukos (GKOS) Q3 Earnings: A Look at Key Metrics
GKOS
Glaukos Q3 Earnings Call Highlights
Glaukos Q3 Earnings Call Highlights
GKOS
Glaukos Announces Third Quarter 2026 Financial Results
Glaukos Announces Third Quarter 2026 Financial Results
GKOS
Glaukos Stock Gains 36.8% in 6 Months: What's Behind the Rally?
Glaukos Stock Gains 36.8% in 6 Months: What's Behind the Rally?
GKOS
Glaukos Strengthens Retinal Pipeline Through RevOpsis Licensing Deal
Glaukos Strengthens Retinal Pipeline Through RevOpsis Licensing Deal
GKOS
Glaukos Announces Positive Topline Results from Phase 4 Prospective Randomized Controlled Clinical Trial Evaluating iDose® TR in Combination with Cataract Surgery
Glaukos Announces Positive Topline Results from Phase 4 Prospective Randomized Controlled Clinical Trial Evaluating iDose® TR in Combination with Cataract Surgery
GKOS
Here's Why You Should Retain Glaukos Stock in Your Portfolio for Now
Here's Why You Should Retain Glaukos Stock in Your Portfolio for Now
GKOSNews tone: automated (AI) classification of the article's content, not a price prediction.
About Glaukos Corp
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. It has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Thomas William Burns | Chairman & CEO | 1961 |
| Mr. Joseph E. Gilliam | President & COO | 1976 |
| Mr. Alex R. Thurman | Senior VP & CFO | 1970 |
| Dr. Tomas Navratil Ph.D. | Chief Development Officer | 1977 |
| Mr. Christopher William Lewis | Vice President of Investor Relations & Corporate Affairs | — |
| Mr. Robert L. Davis J.D. | Senior VP, General Counsel & Business Development | 1966 |
| Ms. Diana A. Scherer | VP of Compliance & Deputy General Counsel | — |
| Ms. Michele M. Allegretto | Senior Vice President of Human Resources | — |
| Mr. L. Jay Katz FACS, M.D. | Chief Medical Officer | — |
| Ms. Tracy M. Founds | Senior Vice President of Global Quality & Medical Safety | — |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 69.63
- MACD 12/26/9
- 18.90
- EMA 9 of MACD
- 15.80
- MACD histogram
- 3.10
- SMA 50
- $181.98
- Price above SMA 50
- EMA 50
- $190.96
- Price above EMA 50
- SMA 200
- $146.02
- Price above SMA 200
- EMA 200
- $150.44
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
10 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $210.00
- Average
- $237.60
- High
- $255.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | -12.2 | +6.5 | ||||||||||
| 2022 | +12.3 | +1.8 | +5.1 | -22.2 | -15.0 | +10.8 | +13.0 | -8.1 | +9.0 | +5.7 | -14.7 | -10.2 |
| 2023 | +11.8 | -5.1 | +3.3 | -4.0 | +20.3 | +21.0 | +10.7 | -2.0 | +0.5 | -4.1 | -8.0 | +22.0 |
| 2024 | +15.5 | -3.6 | +6.2 | +3.1 | +14.0 | +3.5 | -0.2 | +13.8 | -2.0 | +4.5 | +9.0 | +7.8 |
| 2025 | +4.5 | -23.1 | -9.8 | -2.9 | +12.9 | +9.0 | -16.0 | +11.2 | -13.2 | +5.9 | +21.6 | +6.4 |
| 2026 | +7.8 | +2.5 | -11.1 | +27.5 | -26.3 | +35.5 | +21.2 | +5.1 | -7.1 | +45.6 | +3.6 |
